209 related articles for article (PubMed ID: 19509163)
1. Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma.
Huang KH; Huang SF; Chen IH; Liao CT; Wang HM; Hsieh LL
Clin Cancer Res; 2009 Jun; 15(12):4174-80. PubMed ID: 19509163
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Cohen Y; Goldenberg-Cohen N; Shalmon B; Shani T; Oren S; Amariglio N; Dratviman-Storobinsky O; Shnaiderman-Shapiro A; Yahalom R; Kaplan I; Hirshberg A
Oral Oncol; 2011 Oct; 47(10):946-50. PubMed ID: 21824802
[TBL] [Abstract][Full Text] [Related]
3. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.
Park HW; Kang HC; Kim IJ; Jang SG; Kim K; Yoon HJ; Jeong SY; Park JG
Int J Cancer; 2007 Jan; 120(1):7-12. PubMed ID: 17013898
[TBL] [Abstract][Full Text] [Related]
4. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.
Hou P; Ji M; Xing M
Cancer; 2008 Nov; 113(9):2440-7. PubMed ID: 18831514
[TBL] [Abstract][Full Text] [Related]
5. PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): a study on south Indian population.
Sushma PS; Jamil K; Kumar PU; Satyanarayana U; Ramakrishna M; Triveni B
Tumour Biol; 2016 Jun; 37(6):7625-32. PubMed ID: 26687648
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis.
Liao X; Siu MK; Chan KY; Wong ES; Ngan HY; Chan QK; Li AS; Khoo US; Cheung AN
Int J Cancer; 2008 Jul; 123(2):296-302. PubMed ID: 18404674
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
8. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer.
Kim DH; Kim JS; Park JH; Lee SK; Ji YI; Kwon YM; Shim YM; Han J; Park J
Cancer Res; 2003 Oct; 63(19):6206-11. PubMed ID: 14559805
[TBL] [Abstract][Full Text] [Related]
9. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations.
Hesson LB; Wilson R; Morton D; Adams C; Walker M; Maher ER; Latif F
Oncogene; 2005 Jun; 24(24):3987-94. PubMed ID: 15806169
[TBL] [Abstract][Full Text] [Related]
10. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
Nout RA; Bosse T; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; van Eijk R; Ter Haar NT; Smit VT
Gynecol Oncol; 2012 Sep; 126(3):466-73. PubMed ID: 22609107
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
Zhao L; Cui Q; Lu Z; Chen J
Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.
Balgkouranidou I; Matthaios D; Karayiannakis A; Bolanaki H; Michailidis P; Xenidis N; Amarantidis K; Chelis L; Trypsianis G; Chatzaki E; Lianidou ES; Kakolyris S
Mutat Res; 2015 Aug; 778():46-51. PubMed ID: 26073472
[TBL] [Abstract][Full Text] [Related]
13. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.
Endoh H; Yatabe Y; Shimizu S; Tajima K; Kuwano H; Takahashi T; Mitsudomi T
Int J Cancer; 2003 Aug; 106(1):45-51. PubMed ID: 12794755
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma.
Zhang Z; Sun D; Van do N; Tang A; Hu L; Huang G
Int J Cancer; 2007 Jan; 120(1):32-8. PubMed ID: 17013896
[TBL] [Abstract][Full Text] [Related]
15. NDRG2 is a candidate tumor-suppressor for oral squamous-cell carcinoma.
Furuta H; Kondo Y; Nakahata S; Hamasaki M; Sakoda S; Morishita K
Biochem Biophys Res Commun; 2010 Jan; 391(4):1785-91. PubMed ID: 20045673
[TBL] [Abstract][Full Text] [Related]
16. Oncosuppressor methylation: a possible key role in colon metastatic progression.
Tommasi S; Pinto R; Petriella D; Pilato B; Lacalamita R; Santini D; Zito F; Colucci G; Paradiso A; Silvestris N
J Cell Physiol; 2011 Jul; 226(7):1934-9. PubMed ID: 21506124
[TBL] [Abstract][Full Text] [Related]
17. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
18. K-ras mutations and RASSF1A promoter methylation in colorectal cancer.
van Engeland M; Roemen GM; Brink M; Pachen MM; Weijenberg MP; de Bruïne AP; Arends JW; van den Brandt PA; de Goeij AF; Herman JG
Oncogene; 2002 May; 21(23):3792-5. PubMed ID: 12032847
[TBL] [Abstract][Full Text] [Related]
19. Methylation and mutation of the inhibin‑α gene in human melanoma cells and regulation of PTEN expression and AKT/PI3K signaling by a demethylating agent.
Ko H; Ahn HJ; Kim YI
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34958114
[TBL] [Abstract][Full Text] [Related]
20. Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma.
Wang T; Liu H; Chen Y; Liu W; Yu J; Wu G
J Exp Clin Cancer Res; 2009 Dec; 28(1):160. PubMed ID: 20042089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
